文献速递淋巴瘤

ROR1高表达及ROR1信号传导与慢性淋巴细胞白血病对维奈克拉耐药相关

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2022-04-13

研究分析了7例持续维奈克拉治疗后未清除微小残留病灶的慢性淋巴细胞白血病患者,发现其白血病细胞ROR1高表达;治疗1年多后ROR1水平较治疗前显著升高,且Wnt5a诱导的ROR1信号靶基因(含BCL2L1)上调。体外实验表明ROR1信号可增强对维奈克拉的耐药,抗ROR1单抗可抑制该效应。

要点

  • 7例维奈克拉治疗后未清除MRD的CLL患者,其CLL细胞均高表达ROR1。
  • 持续维奈克拉治疗中MRD进展者,复查时ROR1表达显著高于治疗前。
  • Wnt5a诱导的ROR1信号可增强维奈克拉耐药,抗ROR1单抗可抑制。

核心结论

  • Wnt5a诱导的ROR1信号传导可增强慢性淋巴细胞白血病细胞对维奈克拉治疗的耐药。

研究设计与样本

  • 研究纳入7例维奈克拉治疗后未清除微小残留病灶的慢性淋巴细胞白血病患者(CLL1-7),比较治疗前(SC1)与1年多后(SC2)的CLL细胞。
  • 体外转导CLL细胞系MEC1表达ROR1,并检测原代CLL细胞经Wnt5a处理后的维奈克拉敏感性。

主要发现

  • 7例患者(CLL1-7)的CLL细胞均高表达ROR1。
  • SC2时CLL细胞ROR1表达水平显著高于SC1。
  • SC2时Wnt5a诱导的ROR1信号靶基因上调,包括BCL2L1。
  • MEC1表达ROR1后ROR1信号靶基因表达增强、BCL-XL表达升高、对维奈克拉耐药增强,即使表达与维奈克拉耐药相关的BCL2突变型亦如此。
  • Wnt5a处理原代CLL细胞可增加维奈克拉耐药,抗ROR1单抗UC-961(zilovertamab)可抑制该效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the BH3-mimetic venetoclax is highly cytotoxic for chronic lymphocytic leukemia (CLL) cells, some patients with CLL fail to clear minimal residual disease (MRD). We examined the CLL cells of seven such patients (CLL1-7) and found each had high-level expression of ROR1. By examining the CLL cells from such patients prior to therapy at SC1 and then more than 1 year later (Sample Collection 2 (SC2)), when they had progressive increases in MRD despite continued venetoclax therapy, we found the levels of ROR1 expressed on CLL cells at SC2 were significantly higher than that on CLL cells collected at SC1. At SC2, we also observed upregulation of genes induced by Wnt5a-induced ROR1 signaling, including BCL2L1. Transduction of the CLL-cell-line MEC1 to express ROR1 enhanced expression of target genes induced by ROR1-signaling, increased expression of BCL-XL, and enhanced resistance to venetoclax, even in MEC1 made to express mutant forms of BCL2, which are associated with venetoclax resistance. Treatment of primary CLL cells with Wnt5a also increased their resistance to venetoclax, an effect that could be inhibited by the anti-ROR1 mAb (UC-961, zilovertamab). Collectively, these studies indicate that Wnt5a-induced ROR1-signaling can enhance resistance to venetoclax therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ghia EM, Rassenti LZ, Choi MY, et al. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2022. PMID: 35418613. doi:10.1038/s41375-022-01543-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。